Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: wonk who wrote (2528)	7/4/1998 6:05:00 PM
From: Prospector	Read Replies (1) \| Respond to of 5402

Wowie,,, wowie zowie.... wowie,,,,wowie zowie... Prospector (big deal)

To: wonk who wrote (2528)	7/4/1998 6:14:00 PM
From: Prospector	Respond to of 5402

Mr Wonk...hahahaha Zipity do da... zipity ehhh My Oh MY what a wonderful day.. Plenty of sushine headed my way zipity do da zipity ehhhhh.... Mr Wonk ....Mr Blue Birds on My shoulder... Zippity do da zippity ehhh,,,,,, Prospector (hahahhahahaha)

To: wonk who wrote (2528)	7/5/1998 3:14:00 PM
From: dwlima	Respond to of 5402

ok, guys, as you know so much about biotech valuations- why not just provide us with your model, its assumptions and your opinion as to a reasonable valuation for SGNC. oh, and i am really impressed with this author's credentials. Testifying at the state and federal level- he must be really know his stuff to testify in front of a bunch of government people. oh, and thousands of valuations, WOW! i am impressed with how well he markets himself in his book. he may a great person worthy of his merit. but, i have also seen supposed great people with impecible credentials try to prove OJ Simpson not-guilty and that was a no-brainer for anyone with any shrewd of common sense. i only ask that you all use common sense. this goes beyond using common sense for which type of valuation model is appropriate for a biotech company.....i ask that each person here tries to understand whether the people here trying to "HELP" you do a valuation are here for your benefit....or have alterior motives. btw, I really enjoy the non-commital responses and delays i have seen as to what a valuation for SGNC is. i know how important it is for you 2 to have the last word....so, the last words and sentences are yours. i have 45,000 shares and one day they will be worth much more or 0....i like what i have heard and read and i am staying long regardless of what phoney-baloney numbers you guys come up with :) dwlima over and out

To: wonk who wrote (2528)	7/7/1998 9:37:00 AM
From: dwlima	Read Replies (1) \| Respond to of 5402

"For years, the finance literature suggested that there is no acceptable way to map accounting numbers into an estimate of firm value, without first converting the accounting numbers into cash flows. It was pointed out that accounting numbers do not accurately reflect the timing of cash inflows and the investments needed to generate those cash flows (on a side note: see the recent businessweek article on Mr. Chainsaw at Sunbeam). Also, accounting numbers are subject to manipulation and influenced by method choices that should not affect firm value. More RECENTLY, some in both practicing and academic communities have concluded that it is possible to arrive at firm value through accounting numbers, so long as the proper technique is used. IN PRINCIPLE, THE ACCOUNTING-BASED VALUATION SHOULD DELIVER THE SAME ESTIMATE AS DCF. Ok, as for credentials. The book "Business Analysis & Valuation" was written by Dr. Krishna Palepu, Dr. Bernard and Dr Healy. Palepu is a business professor at Harvard. Bernard is the Price Waterhouse Professor of Accounting at the University of Michigan and Healy chairs a seat at MIT. The book was compiled by Ms. Linda Vincent- my valuation professor at the University of Chicago. She failed to list the number of valuations and bios of the authors - but i would imagine they are fairly credible. The interesting thing is that your only proof that discounted earnings is the best way to do a valuation of biotech companies rests completely on what the industry is doing. I have the advantage of questioning things that i come across. It has made me wiser as i uncover the root causes of why things are done a certain way..it also helps me see that some ways are not that good..just there because people are too lazy to change. Btw, you guys are too late.look for a nice price increase this week. I have that loving feeling. dwlima